JP2020533336A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533336A5
JP2020533336A5 JP2020514270A JP2020514270A JP2020533336A5 JP 2020533336 A5 JP2020533336 A5 JP 2020533336A5 JP 2020514270 A JP2020514270 A JP 2020514270A JP 2020514270 A JP2020514270 A JP 2020514270A JP 2020533336 A5 JP2020533336 A5 JP 2020533336A5
Authority
JP
Japan
Prior art keywords
item
rtx
group
preparation
alcoholic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020514270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533336A (ja
JP7358337B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/056944 external-priority patent/WO2019049112A1/en
Publication of JP2020533336A publication Critical patent/JP2020533336A/ja
Publication of JP2020533336A5 publication Critical patent/JP2020533336A5/ja
Priority to JP2022162509A priority Critical patent/JP2022176377A/ja
Application granted granted Critical
Publication of JP7358337B2 publication Critical patent/JP7358337B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020514270A 2017-09-11 2018-09-11 レシニフェラトキシンの製剤 Active JP7358337B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022162509A JP2022176377A (ja) 2017-09-11 2022-10-07 レシニフェラトキシンの製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762556824P 2017-09-11 2017-09-11
US62/556,824 2017-09-11
PCT/IB2018/056944 WO2019049112A1 (en) 2017-09-11 2018-09-11 RESINIFERATOXIN FORMULATION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022162509A Division JP2022176377A (ja) 2017-09-11 2022-10-07 レシニフェラトキシンの製剤

Publications (3)

Publication Number Publication Date
JP2020533336A JP2020533336A (ja) 2020-11-19
JP2020533336A5 true JP2020533336A5 (cg-RX-API-DMAC7.html) 2021-10-21
JP7358337B2 JP7358337B2 (ja) 2023-10-10

Family

ID=63708422

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020514270A Active JP7358337B2 (ja) 2017-09-11 2018-09-11 レシニフェラトキシンの製剤
JP2022162509A Pending JP2022176377A (ja) 2017-09-11 2022-10-07 レシニフェラトキシンの製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022162509A Pending JP2022176377A (ja) 2017-09-11 2022-10-07 レシニフェラトキシンの製剤

Country Status (9)

Country Link
US (3) US20190076396A1 (cg-RX-API-DMAC7.html)
EP (1) EP3681472A1 (cg-RX-API-DMAC7.html)
JP (2) JP7358337B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200051771A (cg-RX-API-DMAC7.html)
CN (1) CN111315360B (cg-RX-API-DMAC7.html)
AU (1) AU2018327301B2 (cg-RX-API-DMAC7.html)
CA (1) CA3074951A1 (cg-RX-API-DMAC7.html)
MX (2) MX2020002692A (cg-RX-API-DMAC7.html)
WO (1) WO2019049112A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11447444B1 (en) 2019-01-18 2022-09-20 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
US11254659B1 (en) 2019-01-18 2022-02-22 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
WO2020226370A1 (ko) 2019-05-09 2020-11-12 주식회사 엘지화학 전기화학소자용 분리막 및 이를 포함하는 전기화학소자
US20230143545A1 (en) * 2020-03-30 2023-05-11 Board Of Regents Of The University Of Nebraska Treating Pulmonary Inflammatory Disease Associated With Covid-19 By Administering Resiniferatoxin
ES3004508T3 (en) * 2020-04-15 2025-03-12 Gruenenthal Gmbh Resiniferatoxin compositions
WO2021257956A1 (en) * 2020-06-19 2021-12-23 Sorrento Therapeutics, Inc. Administration of resiniferatoxin for treatment of bladder pain or bladder cancer
EP4291174A1 (en) * 2021-02-11 2023-12-20 Sorrento Therapeutics, Inc. Administration of resiniferatoxin for treatment of prostate cancer
US20250228765A1 (en) 2024-01-15 2025-07-17 Gruenenthal Gmbh Treating knee joint pain by injecting resiniferatoxin at ultra low doses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2187193B (en) 1986-02-27 1989-11-08 Gerald Scott Controllably and swiftly degradable polymer compositions and films and other products made therefrom
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5232684A (en) 1990-06-29 1993-08-03 The United States Of America As Represented By The Department Of Health And Human Services Labelled resiniferatoxin, compositions thereof, and methods for using the same
US20040146590A1 (en) 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
NZ540769A (en) * 2002-12-18 2009-03-31 Algorx Pharmaceuticals Inc Administration of capsaicinoids for the treatment of pain
CN101119713A (zh) * 2004-11-24 2008-02-06 阿尔高克斯制药公司 类辣椒素凝胶制剂及其用途
EP1838301B1 (de) * 2004-12-28 2015-01-28 Mestex AG Verwendung von resiniferatoxin (rtx) für die herstellung eines mittels zur behandlung von schmerzen
ES2384244T3 (es) * 2004-12-28 2012-07-02 Mestex Ag Utilización de un agonista del receptor vaniloide juntamente con un glicosaminoglicano o un proteoglicano para la fabricación de un fármaco para el tratamiento de los dolores articulares y procedimiento para la aplicación de este fármaco
US9956166B2 (en) * 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
CN113490745A (zh) * 2018-12-21 2021-10-08 索伦托药业有限公司 神经周施用树脂毒素治疗适应不良性疼痛
WO2020154261A1 (en) * 2019-01-22 2020-07-30 Sorrento Therapeutics, Inc. Method for treating osteoarthritis pain by administering resiniferatoxin

Similar Documents

Publication Publication Date Title
Arabi et al. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
RU2607892C2 (ru) Композиции на основе ксилита, препятствующие отделению слизи, а также смежные способы и композиции
HRP20200434T1 (hr) Stabilne vodene formulacije adalimumaba
JP2014139229A5 (cg-RX-API-DMAC7.html)
JP2012505172A5 (cg-RX-API-DMAC7.html)
JOP20250145A1 (ar) صيغ لتركيبات لقاح فيروس حُمى الضنك
AR082024A1 (es) Formulacion de anticuerpo contra ox40l humano
CO6640268A2 (es) Formas de decodificación oral de bendamustina y su uso terapéutico
JP2014530801A5 (cg-RX-API-DMAC7.html)
MX2022012359A (es) Formulacion.
PE20080422A1 (es) Composicion solida antirretroviral de administracion oral
MX2021007393A (es) Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf.
ZA201908610B (en) Il-15 protein complex pharmaceutical composition and uses thereof
JP7358337B2 (ja) レシニフェラトキシンの製剤
Lin et al. Viral infection induces inflammatory signals that coordinate YAP regulation of dysplastic cells in lung alveoli
JP2022511335A5 (cg-RX-API-DMAC7.html)
HRP20160286T1 (hr) Tekuća farmaceutska kompozicija koja sadrži nitizinon
PH12021551226A1 (en) Monomethyl fumarate-carrier conjugates and methods of their use
MX2022000267A (es) Composiciones comprimidas de macitentan, metodos y usos de las mismas.
ES2239802T3 (es) Composiciones farmaceuticas.
FI3554474T3 (fi) Mikafungiinikoostumuksia
JP2016534062A5 (cg-RX-API-DMAC7.html)
BRPI0508798A (pt) formulação lìquida de hormÈnio de crescimento, composição farmacêutica, forma de apresentação da formulação lìquida de hormÈnio de crescimento e uso da formulação lìquida de hormÈnio de crescimento
WO2020053658A3 (en) Non-aqueous chemotherapeutic solutions for oral dosage
AR062674A1 (es) Formulacion acuosa que comprende un agente antitumoral